Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A phase II trial of bryostatin 1 in the treatment of metastatic colorectalcancer
Autore:
Zonder, JA; Shields, AF; Zalupski, M; Chaplen, R; Heilbrun, LK; Arlauskas, P; Philip, PA;
Indirizzi:
Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Div Hematol & Oncol, Detroit, MI 48201 USA Wayne State Univ Detroit MI USA 48201 atol & Oncol, Detroit, MI 48201 USA
Titolo Testata:
CLINICAL CANCER RESEARCH
fascicolo: 1, volume: 7, anno: 2001,
pagine: 38 - 42
SICI:
1078-0432(200101)7:1<38:APITOB>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
PROTEIN-KINASE-C; CHRONIC LYMPHOCYTIC-LEUKEMIA; COLONY-STIMULATING FACTOR; NECROSIS-FACTOR-ALPHA; CELL-LINE; FLUOROURACIL FAILURE; AGENT BRYOSTATIN-1; RANDOMIZED TRIAL; CARCINOMA CELLS; GROWTH-FACTORS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
56
Recensione:
Indirizzi per estratti:
Indirizzo: Philip, PA Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Div Hematol & Oncol, 509 Hudson Bldg,3990 John R St, Detroit, MI 48201 USA Wayne State Univ 509 Hudson Bldg,3990 John R St Detroit MI USA 48201
Citazione:
J.A. Zonder et al., "A phase II trial of bryostatin 1 in the treatment of metastatic colorectalcancer", CLIN CANC R, 7(1), 2001, pp. 38-42

Abstract

Current chemotherapy for patients with advanced colorectal cancer is relatively ineffective and may be associated with significant toxicity. Bryostatin 1 (bryo 1) influences cell proliferation, intracellular metabolism and signaling, differentiation, and apoptosis in human canter cell lines via modulation of protein kinase C (PKC) activity, This trial investigates the efficacy and toxicity of bryo 1 as a novel therapeutic agent for patients withadvanced colorectal cancer who have had previous 5-fluorouracil therapy. The primary end point was tumor response to bryo 1, Toxicity was also assessed. Twenty-eight patients with advanced colorectal cancer were enrolled. The mean age was 59 years (range, 38-76), with 16 men and 12 women, and good minority representation (11 African-Americans). The first 10 patients initially received 25 (I)mug/m(2) of bryo 1 weekly as a 24-h infusion for 3 weeks of every 4-week cycle, with dose escalation to 35 mug/m(2) starting with the second cycle. The remaining patients were started at 35 mug/m(2) and escalated to 40 mug/m(2), if toxicity was minimal. Twenty-five patients were evaluable for objective tumor response, and complete data on toxicity were collected on 26 patients. No partial or complete tumor responses were observed. All 25 patients had disease progression within four cycles, Myalgia was the most common toxicity, Myelosuppression was not seen. bryo 1 as a weekly 24-h continuous infusion lacks single-agent antitumor activity in advanced colorectal cancer. Toxicity differs from that of traditional chemotherapeutic drugs.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/05/20 alle ore 14:42:37